Natural products in clinical trials: Antibacterial and antifungal agents

Yaoxue Xuebao

Volumn 42, Issue 3, 2007, Pages 236-244

  Han, Li ^a   Zheng, Dan ^a   Huang, Xue Shi ^a   Yu, Shi Shan ^b   Liang, Xiao Tian ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antibacterial; Antifungal; Clinical trails; Natural products

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT; ECHINOCANDIN; NEW DRUG; PARTRICIN; POLYENE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BIOLOGICAL PRODUCTS; DRUG RESISTANCE, MICROBIAL; DRUGS, INVESTIGATIONAL; ECHINOCANDINS; HUMANS; MOLECULAR STRUCTURE; POLYENES;

EID: 34247627590     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Newman DJ, Cragg CM, Snader KM. The influence of natural products upon drug discovery [J]. Nat Prod Rep, 2000,17:215-234.
2. Buss AD, Cox B, Waigh RD. Burger's Medicinal Chemistry and Drug Discovery. Vol 1: Drug Discovery [M]. 6 Ed. Wiley: Hoboken, New Jersey, 2003:847-900.
3. Grabley S, Thiericke R. Drug Discovery from Nature [M]. Berlin: Springer, 2000:3-37.
4. Cordell GA. Natural products in drug discovery- creating a new vision [J]. Phytochem Rev, 2002,1:261-273.
5. Strohl WR. The role of natural product in a modern drug discovery program [J]. Drug Discov Today, 2000, 5: 39-41.
6. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002 [J]. J Nat Prod, 2003,66:1022-1037.
7. Butler MS. The role of natural product chemistry in drug discovery [J]. J Nat Prod, 2004,67:2141-2153.
8. Shu YZ, Recent natural products based drug development: a pharmaceutical industry perspective [J]. J Nat Prod, 1998,61:1053-1071.
9. Nathan C. Antibiotics at the crossroads [J]. Nature, 2004,431:899-902.
10. Bush K, Macielag M, Weidner WM. Taking inventory. antibacterial agents currently at / or beyond phase I [J]. Curr Opin Microbiol, 2004,7:466-476.
11. Rogers BL. Bacterial targets to antimicrobial leads and development candidates [J]. Curr Opin Drug Discov Dev, 2004,7:211-222.
12. Singh GS. Beta-lactams in the new millennium Part-I: monobactams and carbapenems [J]. Mini Rev Med Chem, 2004,4:69-92.
13. Kasai M, Hatano S, Kitagawa M, et al. AS-924, a novel bifunctional prodrug of ceftizoxime [J]. J Antibiot, 1999,52:491-500.
14. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers [J]. Antimicrob Agents Chemother, 2004,48:2576-2580.
15. Louie A, Liu W, Deziel MR, et al. Presented at the 44th ICAAC Conference [C]. Washington DC : 2004 : Poster A-1866.
16. Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel n-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties [J]. Bioorg Med Chem, 2003,11:2427-2437.
17. Butler MS. Natural products to drugs: natural product derived compounds in clinical trials [J]. Nat Prod Rep, 2005,22:162-195.
18. Thomson KS, Moland ES. CS-023, a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and pscudomonas aeruginosa [J]. J Antimicrob Chemother, 2004,54:557-562.
19. Meiji Seika Kaisha. Tebipenem (ME-1211) [EB/OL]. Meiji Seika Kaisha: [2004-11-01] http://www.mei.ji.co.jp/iyaku/rd/rd_pipeline.html.
20. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens [J]. Antimicrob Agents Chemother, 2004,48:3136-3140.
21. Gao Y. Glycopeptide antibiotics and development of inhibitors to overcome vanco mycin resistance [J]. Nat Prod Rep, 2002,19:100-107.
22. Bambeke VF, Laethem VY, Courvalin P, et al. Glycopeptide antibiotics: from conven tional molecules to new derivatives [J]. Drugs, 2004,64:913-936.
23. Guay DR. Dalbavancin: an investigational glycopeptide [J]. Expert Rev Anti Infect Ther, 2004,2:845-852.
24. Vicuron Pharmaceuticals. Vicuron pharmaceuticals submits new drug application for dalba vancin to U. S. Food and Drug Administration [EB/OL]. Vicuron Pharmaceuticals: [2004-12-21] http://www.vicuron.com.
25. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-Positive bacteria [J]. Antimicrob Agents Chemother, 2004,48:3043-3050.
26. Barrett JF. Oritavancin Eli Lilly Co [J]. Curr Opin Investig Drugs, 2001,2:1039-1044.
27. InterMune. InterMune charts new course for future [EB/OL]. InterMune: [2004-03-31] http://www.intermune.com.
28. Jiang W, Wanner J, Lee RJ, et al. Total synthesis of the ramoplanin A2 and ramoplan ose aglycon [J]. J Am Chem Soc, 2003,125:1877-1887.
29. Chen L, Yuan Y, Helm JS, et al. Dissecting ramoplanin : mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics [J]. J Am Chem Soc, 2004,12:7462-7463.
30. Gastaldo L, Marinelli F. Changes in GE2270 antibiotic production in planobisporarosea through modulation of methylation metabolism [J]. Microbiology, 2003,149:1523-153.
31. Abu-Gharbieh E, Vasina V, Poluzzi E, et al. Antibacterial macrolides: a drugs class with a complex pharmacological profile [J]. Pharmacol Res, 2004,50:211-222.
32. Wang G, Niu D, Qiu YL, et al. Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation [J]. Org Lett, 2004,6:4455-4458.
33. Enanta Pharmaceuticals. Enanta Pharmaceuticals announces initiation of phase II studies in north America on first-in-class antibiotic EDP-420 for the treatment of community acquired pneumonia [EB/OL]. Enanta Pharmaceuticals: [2006-01-19] http;//www.enanta.com.
34. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines : a comparative review with the tetracyclines [J]. Drugs, 2004,64:63-88.
35. Madison NJ. Wyeth seeks global regulatory approval of Tygacil (Tigecycline) for injection [EB/OL]. Wyeth Pharmaceuticals: [2004-12-15] http://www.wyeth.com.
36. Lounis N, Roscigno G. In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections [J]. Curr Pharm Des, 2004,10:3229-3238.
37. Springer DM, Sorenson ME, Huang S, et al. Synthesis and activity of a C-8 keto pleuromutilin derivative [J]. Bioorg Med Chem Lett, 2003,13:1751-1753.
38. Sneader W. Drug Prototypes and their Exploitation [M]. Chichester: Wiley, 1996:525-532.
39. Kidwai M, Venkataramanan R, Rastogi S, et al. Discovery and development of antufungal compounds [J]. Curr Med Chem Anti-Infect Agents, 2003,2:27-71.
40. Girmenia C, Martino P, New antifungal drugs and new clinical trials: interpreting results may be difficult [J]. Curr Opin Oncol, 2003,15:283-288.
41. Denning DW. Echinocandin antifungal drugs [J]. Lancet, 2003,362:1142-1151.
42. Keating G, Figgitt D, Caspofungin: a review of its use in esophageal candidiasis, invasive candidiasis and invasive aspergillosis [J]. Drugs, 2003,63:2235-2263.
43. Jarvis B, Friggitt DP, Scott LJ. Micafungin [J]. Drugs, 2004,64:969-982.
44. Murdoch D, Plosker GL. Anidulafungin [J]. Drugs, 2004,64:2249-2258.
45. Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model [J]. Antimicrob Agents Chemother, 2003,47-1187-1192.
46. Volpon L, Lancelin JM. Solution NMR structure of five representative glycosylated polyene macrolide antibiotics with a sterol-dependent antifungal activity [J]. Eur J Biochem, 2002,269:4533-4541.
47. Mozzi GP, Bruzzese BT, Galmozzi MR, et al. The use of lipid emulsions for the iv administration of a new water soluble polyene antibiotic, SPK-843 [J]. J Antimicrob Chemother, 2002,49:321-325.
48. Petraitis V, Petraitiene R, Kelaher AM, et al. Efficacy of PLD-118, a novel inhibitor of Candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans [J]. Antimicrob Agents Chemother, 2004,48: 3959-3967.